Drug firm Alembic Pharmaceuticals Ltd has entered into oncology segment by inaugurating a Rs 300 crore anti-cancer drug facility at Halol in Gujarat.

The unit will manufacture 60 million tablets or capsules and approximately 20 million vials of liquid injectable and lyophilized concentrates.

With this facility, the Alembic Pharma will commence exporting oncology products to US, Middle East, North Africa, Australia and South Africa.

The facility has equipment from BOSCH of Germany, GEA of Belgium, Alexanderwerk from UK, ICOS from Italy, Tofflon from China.

The company hopes to invest Rs 1,500 crore as part of its expansion plan over the next three years period, which will be funded through debt and internal accruals.

APL has recently invested in an ultra-modern R&D centre at Hyderabad. APL is one of the leading players in the industry to have invested about 11 per cent of its turnover in R&D.

The Gujarat state government hopes to launch 1,000 generic medical stores in 2017 from the present 250 stores, which will help in providing cheap quality drugs to people of the state